Partial depletion of tissue factor pathway inhibitor during subcutaneous administration of unfractionated heparin, but not with two low molecular weight heparins

British Journal of Haematology

Volumn 107, Issue 4, 1999, Pages 756-762

  Bendz, Bjørn ^a   Hansen, John Bjarne ^c   Andersen, Trine O ^a   Østergaard, Per ^b   Sandset, Per Mortem ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b NOVO NORDISK A S   (Denmark)

^c NONE

Author keywords

Anticoagulant therapy; Low molecular weight heparin; Tissue factor; Tissue factor pathway inhibitor; Unfractionated heparin

Indexed keywords

BLOOD CLOTTING FACTOR 10A; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PROTHROMBIN A; TISSUE FACTOR PATHWAY INHIBITOR;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG ADMINISTRATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0033399065     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1999.01791.x     Document Type: Article

References (37)

1. Abumiya, T., Enjyoji, K., Kokawa, T., Kamikubo, Y. & Kato, H. (1995) An anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody recognized the third Kunitz domain (K3) of free-form TFPI but not lipoprotein-associated forms in plasma. Journal of Biochemistry, 118, 178-182.
2. Bajaj, M.S., Kuppuswamy, M.N., Saito, H., Spitzer, S.G. & Bajaj, S.P. (1990) Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: evidence that endothelium is the principal site of its synthesis. Proceedings of the National Academy of Sciences of the United States of America, 87, 8869-8873.
3. Bergqvist, D., Hedner, U., Sjorin, E. & Holmer, E. (1983) Anti-coagulant effects of two types of low molecular weight heparin administered subcutaneously. Thrombosis Research, 32, 381-391.
4. Broze, G.J., Jr (1995) Tissue factor pathway inhibitor. Thrombosis and Haemostasis, 74, 90-93.
5. Broze, G.J., Jr & Miletich, J.P. (1987) Characterization of the inhibition of tissue factor in serum. Blood, 69, 150-155.
6. Cohen, M., Demers, C., Gurfinkel, E.P., Turpie, A.G., Fromell, G.J., Goodman, S., Langer, A., Califf, R.M., Fox, K.A., Premmereur, J. & Bigonzi, F. (1997) A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. New England Journal of Medicine, 337, 447-452.
7. Falkon, L., Gari, M., Barbanoj, M., Amiral, J. & Fontcuberta, J. (1998) Tissue factor pathway inhibitor and anti-FXa kinetic profiles of a new low-molecular-mass heparin, Bemiparin, at therapeutic subcutaneous doses. Blood Coagulation and Fibrinolysis, 9, 137-141.
8. Girard, T.J., Warren, L.A., Novotny, W.F., Likert, K.M., Brown, S.G., Miletich, J.P. & Broze, G.J., Jr (1989) Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature, 338, 518-520.
9. Hansen, J.B., Huseby, K.R., Huseby N-E., Ezban, M. & Nordoy, A. (1997) Tissue factor pathway inhibitor in complex with low density lipoprotein isolated from human plasma does not possess anticoagulant function in tissue factor induced coagulation in vitro. Thrombosis Research, 85, 413-425.
10. Hansen, J.B., Huseby, K.R., Huseby, N.E., Sandset, P.M., Hanssen, T.A. & Nordoy, A. (1995) Effect of cholesterol lowering on intravascular pools of TFPI and its anticoagulant potential in type II hyperlipoproteinemia. Arteriosclerosis, Thrombosis and Vascular Biology, 15, 879-885.
11. Hansen, J.B., Sandset, P.M., Huseby, K.R., Huseby, N.E., Bendz, B., Ostergaard, P. & Nordoy, A. (1998) Differential effect of unfractionated heparin and low molecular weight heparin on intravascular tissue factor pathway inhibitor: evidence for a difference in antithrombotic action. British Journal of Haematology, 101, 638-646.
12. Hansen, J.B., Sandset, P.M., Huseby, K.R., Huseby, N.E. & Nordoy, A. (1996) Depletion of intravascular pools of tissue factor pathway inhibitor (TFPI) during repeated or continuous intravenous infusion of heparin in man. Thrombosis and Haemostasis, 76, 703-709.
13. Hemker, H.C. & Beguin, S. (1990) Mode of action of unfractionated and low molecular weight heparins on the generation of thrombin in plasma. Haemostasis, 20, Suppl. 1, 81-92.
14. Holst, J., Lindblad, B., Bergqvist, D., Hedner, U., Nordfang, O. & Ostergaard, P. (1997) The effect of protamine sulphate on plasma tissue factor pathway inhibitor released by intravenous and subcutaneous unfractionated and low molecular weight heparin in man. Thrombosis Research, 86, 343-348.
15. Hubbard, A.R., Weller, L.J. & Gray. E. (1994) Measurement of tissue factor pathway inhibitor in normal and post-heparin plasma. Blood Coagulation and Fibrinolysis, 5, 819-823.
16. Hull, R.D., Raskob, G.E., Pineo, G.F., Green, D., Trowbridge, A.A., Elliott, C.G., Lerner, R.G., Hull, J., Sparling, T. & Brettell, H.R. (1992) Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. New England Journal of Medicine, 326, 975-982.
17. Iversen, N., Lindahl, A.K., Abildgaard, U., Sandset, P.M. & Torjesen, P.A. (1998) Elevated TFPI in malignant disease: relation to cancer type and hypercoagulation binding of tissue factor pathway inhibitor to cultured endothelial cells-influence of glycosamino-glycans. British Journal of Haematology, 102, 889-895.
18. Iversen, N., Sandset, P.M., Abildgaard, U. & Torjesen, P.A. (1996) Binding of tissue factor pathway inhibitor to cultured endothelial cells-influence of glycosaminoglycans. Thrombosis Research, 84, 267-278.
19. Leizorovicz, A., Simonneau, G., Decousus, H. & Boissel, J.P. (1994) Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta-analysis. British Medical Journal, 309, 299-304.
20. Lindahl, A.K., Sandset, P.M. & Abildgaard, U. (1992) The present status of tissue factor pathway inhibitor. Blood Coagulation and Fibrinolysis, 3, 439-449.
21. Nordfang, O., Bjorn, S.E., Valentin, S., Nielsen, L.S., Wildgoose, P., Beck, T.C. & Hedner, U. (1991) The C-terminus of tissue factor pathway inhibitor is essential to its anticoagulant activity. Biochemistry, 30, 10371-10376.
22. Novotny, W.F., Brown, S.G., Miletich, J.P., Rader, D.J. & Broze, G.J., Jr (1991) Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Blood, 78, 387-393.
23. Novotny, W.F., Girard, T.J., Miletich, J.P. & Broze, G.J., Jr (1988) Platelets secrete a coagulation inhibitor functionally and anti-genically similar to the lipoprotein associated coagulation inhibitor. Blood, 72, 2020-2025.
24. Novotny, W.F., Girard, T.J., Miletich, J.P. & Broze, G.J., Jr (1989) Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma. Journal of Biological Chemistry, 264, 18832-18837.
25. Ostergaard, P.B., Beck, T.C., Orsted, H., Svendsen, A., Nordfang, O., Sandset, P.M. & Hansen, J.B. (1997) An enzyme linked immunosorption assay for tissue factor pathway inhibitor. Thrombosis Research, 87, 447-459.
26. Prandoni, P., Lensing, A.W., Buller, H.R., Carta, M., Cogo, A., Vigo, M., Casara, D., Ruol, A. & ten Cate, J.W. (1992) Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet, 339, 441-445.
27. Rao, L.V. & Rapaport, S.I. (1987) Studies of a mechanism inhibiting the initiation of the extrinsic pathway of coagulation. Blood, 69, 645-651.
28. Samama, M.M., Bara, L. & Gerotziafas, G.T. (1994) Mechanisms for the antithrombotic activity in man of low molecular weight heparins (LMWHs). Haemostasis, 24, 105-117.
29. Sandset, P.M. (1999) Tissue factor pathway inhibitor (TFPI). Laboratory Techniques in Thrombosis, a Manual (2nd revised edn of ECAT Assay Procedures) (ed. by J. Jesperscn, R. M. Bertina and F. Haverkate), pp. 171-181.
30. Sandset, P.M., Abildgaard, U. & Larsen, M.L. (1988) Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thrombosis Research, 50, 803-813.
31. Sandset, P.M., Abildgaard, U. & Pettersen, M. (1987) A sensitive assay of extrinsic coagulation pathway inhibitor (EPI) in plasma and plasma fractions. Thrombosis Research, 47, 389-400.
32. Sandset, P.M., Larsen, M.L., Abildgaard, U., Lindahl, A.K. & Odegaard, O.R. (1991) Chromogenic substrate assay of extrinsic pathway inhibitor (EPI): levels in the normal population and relation to cholesterol. Blood Coagulation and Fibrinolysis, 2, 425-433.
33. Siragusa, S., Cosmi, B., Piovella, F., Hirsh, J. & Ginsberg, J.S. (1996) Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. American Journal of Medicine, 100, 269-277.
34. Valentin, S., Larnkjer, A., Ostergaard, P., Nielsen, J.I. & Nordfang, O. (1994) Characterization of the binding between tissue factor pathway inhibitor and glycosaminoglycans. Thrombosis Research, 75, 173-183.
35. Wesselschmidt, R., Likert, K., Girard, T., Wun, T.C. & Broze, G.J., Jr (1992) Tissue factor pathway inhibitor: the carboxy-terminus is required for optimal inhibition of factor Xa. Blood, 79, 2004-2010.
36. Wesselschmidt, R., Likert, K., Huang, Z., MacPhail, L. & Broze, G.J., Jr (1993) Structural requirements for tissue factor pathway inhibitor interactions with factor Xa and heparin. Blood Coagulation and Fibrinolysis, 4, 661-669.
37. Wun, T.C., Kretzmer, K.K., Girard, T.J., Miletich, J.P. & Broze, G.J., Jr (1988) Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains. Journal of Biological Chemistry, 263, 6001-6004.